Novartis AG Stock Performance
Novartis AG shares have experienced notable downward pressure in recent months, trading at $138.62 per SID market data. The stock has declined 8.39% over the past month and 9.2% over the trailing three-month period, though it retains a positive 9.83% return over the past year. NVS is currently trading well below both its 50-day moving average of $153.72 and its 200-day moving average of $149.83, indicating sustained bearish momentum according to Massive/Polygon technical indicators. The 14-day relative strength index stands at 30.4, placing the stock near oversold territory and suggesting selling pressure may be approaching exhaustion. Novartis maintains a market capitalization of approximately $259 billion and a beta of 0.438, reflecting significantly lower volatility than the broader market. Average daily trading volume stands at approximately 1.65 million shares, indicating consistent institutional participation in the name.
Novartis AG Valuation Analysis
Novartis AG currently trades at a price-to-earnings ratio of 18.18, per SID market data, positioning the company within a moderate valuation range for the healthcare sector. The price-to-book ratio stands at 5.90, reflecting the premium typically assigned to large-cap pharmaceutical companies with substantial intangible asset portfolios. Notably, the PEG ratio registers at negative 0.79, according to SEC filings and consensus estimates, which limits its utility as a growth-adjusted valuation metric in the current context. Novartis offers a dividend yield of approximately 3.31%, providing meaningful income for shareholders and comparing favorably against broader market averages. This yield has effectively increased as the stock price has declined over recent months. Within the healthcare sector, the combination of a sub-20 P/E ratio and above-average dividend yield positions Novartis as a value-oriented large-cap pharmaceutical holding based on current fundamental metrics.
Smart Money Activity for NVS
Novartis AG registers a composite smart money score of 58 out of 100, reflecting a neutral overall signal per SID market data. The institutional component leads with a score of 21.0 out of 25, indicating strong positioning and sustained interest from major fund managers as reported in 13F institutional filings. Insider activity scores 12.5 out of 25, suggesting a balanced pattern of neither aggressive buying nor concentrated selling by corporate officers and directors according to SEC Form 4 filings. Dark pool trading activity scores 12.0 out of 25, pointing to moderate levels of off-exchange institutional block trading without a discernible directional bias. Congressional trading activity registers at 12 out of 25, reflecting limited notable legislative portfolio adjustments involving NVS shares. The relatively high institutional score contrasted against middling insider and dark pool readings produces the overall neutral composite signal, suggesting large institutional holders are maintaining positions while other smart money cohorts remain inactive directionally.
Novartis AG Earnings Outlook
Novartis AG reported mixed recent quarterly results according to company earnings reports. In the most recent completed quarter, the company delivered earnings per share of $2.41 against analyst estimates of $2.16, representing a positive surprise of $0.25 or approximately 11.6%. This followed a prior quarter where Novartis reported EPS of $1.99, missing the consensus estimate of $2.07 by $0.08. Looking ahead, analyst estimates project EPS of $2.10 for the upcoming quarter with results expected on May 1, 2026, followed by an estimated $2.13 for the subsequent quarter with a July 16, 2026 reporting date. The sequential increase in forward estimates from $2.10 to $2.13 reflects modest expected earnings growth. The strong beat in the latest reported quarter demonstrates operational execution capability, though the prior-quarter miss underscores variability in results. The next earnings release on April 28, 2026 will be a key catalyst for the stock.
Wall Street Analyst Ratings for NVS
Wall Street analyst sentiment on Novartis AG remains divided based on recent coverage updates. On July 14, 2026, TD Cowen maintained its Hold rating on NVS, while Berenberg similarly reiterated a Hold rating on July 13, per Wall Street analyst reports. On the same date, Rothschild & Co Redburn maintained its Sell rating, representing the most bearish stance among recent coverage. Conversely, Argus Research Corporation upgraded NVS to Buy from Hold on July 9, 2026, marking the most notable rating change in the recent cycle. Intesa Sanpaolo Equity Research reiterated its Buy rating on June 30, 2026, per SID consensus data. The distribution across the five most recent actions shows two Buy ratings, two Hold ratings, and one Sell rating, reflecting a lack of firm directional consensus. The Argus upgrade to Buy from Hold stands out as the sole directional change, while the remaining four actions represent reiterations of existing positions on the stock.
